Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 8/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7940789 | 0.88 | BACE1 (0.53) | KMT2AMEN1ALOX12RAB9ABACE1 | |
| SCHEMBL7941927 | 0.86 | POLB (0.46) | TP53NPC1RAB9ABACE1HTT | |
| SCHEMBL7945350 | 0.86 | BACE1 (0.47) | TP53NPC1RAB9ABACE1GLA | |
| SCHEMBL7942892 | 0.85 | BACE1 (0.61) | KMT2AMEN1ALOX12TP53NPC1 | |
| SCHEMBL7944281 | 0.84 | ALOX12 (0.53) | KMT2AMEN1ALOX12TP53NPC1 | |
| SCHEMBL7945352 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL7941880 | 0.82 | SMN1; SMN2 (0.57) | TP53NPC1RAB9ABACE1HTT | |
| SCHEMBL7943391 | 0.81 | MEN1 (0.46) | KMT2AMEN1NPC1RAB9ABACE1 | |
| SCHEMBL7941932 | 0.81 | NPC1 (0.46) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL12301465 | 0.81 | NPC1 (0.53) | KMT2AMEN1TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | KMT2A 1020/4885MEN1 1150/4885ALOX12 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.